NASDAQ:AVXS AveXis (AVXS) Stock Price, News & Analysis → A new way to collect income from stocks (From DTI) (Ad) Free AVXS Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$217.83▼$217.8350-Day Range N/A52-Week Range$65.54▼$217.94Volume222 shsAverage Volume816,305 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get AveXis alerts: Email Address Ad Banyan Hill PublishingForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)Watch my video for all of the details About AveXis Stock (NASDAQ:AVXS)AveXis, Inc., a clinical-stage gene therapy company, engages in developing and commercializing treatments for patients suffering from rare and life-threatening neurological genetic diseases. Its initial product candidate is AVXS-101, a gene therapy product candidate that has completed Phase I clinical trial for the treatment of spinal muscular atrophy Type 1. The company also intends to identify, acquire, develop, and commercialize gene therapy product candidates for the treatment of other rare and life-threatening neurological genetic diseases. It has strategic collaboration and license agreements with Nationwide Children's Hospital; The Research Institute at Nationwide Children's Hospital; REGENXBIO Inc.; and Asklepios Biopharmaceutical, Inc. The company was formerly known as BioLife Cell Bank, Inc. and changed its name to AveXis, Inc. in January 2014. AveXis, Inc. was founded in 2010 and is headquartered in Bannockburn, Illinois.Read More Ad Banyan Hill PublishingForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)Watch my video for all of the details AVXS Stock News HeadlinesMay 25, 2023 | finance.yahoo.comNovartis ‘focusing on high-end, innovative medicines,’ CEO saysJanuary 2, 2023 | thestreet.comIonis Childhood Spine Disorder Drug Notches Pivotal Study Win, Triggers Biogen OptionApril 28, 2024 | Insiders Exposed (Ad)The Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.September 21, 2022 | bizjournals.comGoogle-backed gene therapy firm launches Morrisville manufacturing facility - The Business JournalsSeptember 15, 2022 | seekingalpha.comRegenxbio Stock: A Transformative Year (NASDAQ:RGNX) - Seeking AlphaSeptember 12, 2022 | finance.yahoo.comGenSight Biologics Strengthens Its Management Team to Support the Launch of LUMEVOQ® in Europe - Yahoo FinanceAugust 29, 2022 | seekingalpha.comREGENXBIO: Gene Therapy Pioneer Moving To Late-Stage Development (NASDAQ:RGNX) - Seeking AlphaAugust 29, 2022 | dallasnews.comOnce high-flying Dallas biotech sees promising drug data amid growing financial pressure - The Dallas Morning NewsApril 28, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. August 20, 2022 | bizjournals.comIt's in our DNA: Why the Columbus Region is a hub for gene therapy companies - Columbus Business First - The Business JournalsAugust 17, 2022 | streetinsider.comRelief Therapeutics Appoints David McCullough as Head of U.S. Market Access - StreetInsider.comJuly 20, 2022 | prnewswire.comPopular Open Source GraphQL Company Dgraph Secures $6M in Seed Round with New Leadership - PR NewswireJuly 18, 2022 | globenewswire.comGeneration Bio Appoints Dannielle Appelhans to Its Board of Directors - GlobeNewswireJune 9, 2022 | finance.yahoo.comGlobal Cell and Gene Therapy Market Analysis/Opportunities Report 2022-2035: Niche Startups are Spearheading the Innovation in this Domain - Yahoo FinanceJune 9, 2022 | prnewswire.comGlobal Cell and Gene Therapy Market Analysis/Opportunities Report 2022-2035: Niche Startups are Spearheading the Innovation in this Domain - PR NewswireJune 8, 2022 | globenewswire.comGlobal Cell and Gene Therapy Market Investor/Opportunities Report 2022: Evaluate the Current/Future Potential Over the Coming Decades - GlobeNewswireJune 7, 2022 | seekingalpha.comBLUE stock drives gene therapy stocks higher after FDA review (NASDAQ:BLUE) - Seeking AlphaMay 3, 2022 | finance.yahoo.comSumo Logic Appoints John D. Harkey, Jr. to Board of Directors - Yahoo FinanceApril 21, 2022 | streetinsider.comSatellite Bio Reveals Pioneering Tissue Therapeutics, Bioengineered Tissues That Restore Organ Function, Bringing Hope Across Diseases - StreetInsider.comApril 20, 2022 | seekingalpha.comRegenxbio: Is The Ultimate Catalyst Coming? - Seeking AlphaApril 20, 2022 | businesswire.comSatellite Bio Reveals Pioneering Tissue Therapeutics, Bioengineered Tissues That Restore Organ Function, Bringing Hope Across Diseases - Business WireMarch 29, 2022 | bizjournals.comSamsung invests in Chicago biotech Jaguar Gene Therapy - The Business JournalsMarch 29, 2022 | finance.yahoo.comNkarta Appoints Manufacturing Technology Executive, Angela Thedinga, to Board of Directors - Yahoo FinanceMarch 9, 2022 | finance.yahoo.comTScan Therapeutics Reports Full Year 2021 Financial Results and Highlights Key 2022 Priorities - Yahoo FinanceMarch 7, 2022 | seekingalpha.comTaysha Gene Therapies Gets A 'Thumbs Up' - Seeking AlphaMarch 5, 2022 | theguardian.com'It's a real-life Hunger Games': a lifesaving drug costs $2m, but not every child can get it - The GuardianFebruary 14, 2022 | prnewswire.comNEW STATE AVIATION HOLDINGS NAMES CEO AND CFO - PRNewswireSee More Headlines Receive AVXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AveXis and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2018Today4/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:AVXS CUSIPN/A CIK1652923 Webwww.avexis.com Phone847-572-8280FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableOptionable BetaN/A Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Sean P. Nolan (Age 50)Chief Exec. Officer, Pres and Director Dr. Sukumar Nagendran M.D. (Age 51)Chief Medical Officer and Sr. VP Mr. Phillip B. Donenberg CPA (Age 57)Sr. VP, CFO & Principal Accounting Officer Mr. Brian K. Kaspar Ph.D. (Age 44)Chief Scientific Officer, Director and Member of Scientific Advisory Board Mr. Michael B. Johannesen (Age 52)Chief Compliance Officer, Sr. VP and Gen. Counsel Key CompetitorsGenocea BiosciencesNASDAQ:GNCAQVectivBioNASDAQ:VECT180 Life SciencesNASDAQ:ATNFW60 Degrees PharmaceuticalsNASDAQ:SXTPWAclarionNASDAQ:ACONWView All Competitors AVXS Stock Analysis - Frequently Asked Questions How were AveXis' earnings last quarter? AveXis, Inc. (NASDAQ:AVXS) issued its quarterly earnings results on Wednesday, May, 9th. The company reported ($6.20) EPS for the quarter, missing the consensus estimate of ($3.32) by $2.88. What other stocks do shareholders of AveXis own? Based on aggregate information from My MarketBeat watchlists, some companies that other AveXis investors own include REGENXBIO (RGNX), bluebird bio (BLUE), Exelixis (EXEL), Mallinckrodt (MNK), AbbVie (ABBV), Salesforce (CRM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), Momenta Pharmaceuticals (MNTA) and Neurocrine Biosciences (NBIX). When did AveXis IPO? AveXis (AVXS) raised $86 million in an initial public offering (IPO) on Thursday, February 11th 2016. The company issued 4,300,000 shares at a price of $19.00-$21.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and BMO Capital Markets and Chardan were co-managers. This page (NASDAQ:AVXS) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsProtect Your Bank Account Before It’s Too LateWeiss RatingsHe Is Giving Away BitcoinCrypto Swap ProfitsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressJeff Bezos Just Humiliated Elon MuskInvestorPlaceThe World's First "$20 Trillion Drug?"Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AveXis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
